|
n (%)
|
irRC
|
RECIST
|
|---|
|
Immunotherapy-Naive (n = 39)
|
Prior Immunotherapy (n = 11)
|
Immunotherapy-Naive (n = 39)
|
Prior Immunotherapy (n = 11)
|
|---|
|
Objective response rate
|
10 (25.6)
|
0
|
9 (23.1)
|
0
|
|
Complete response
|
3 (7.7)
|
0
|
3 (7.7)
|
0
|
|
Partial response
|
7 (17.9)
|
0
|
6 (15.4)
|
0
|
|
Stable disease
|
15 (38.5)
|
4 (36.4)
|
10 (25.6)
|
3 (27.3)
|
|
Disease control rate
|
25 (64.1)
|
4 (36.4)
|
19 (48.7)
|
3 (27.3)
|
|
Progressive disease
|
7 (17.9)
|
5 (45.5)
|
15 (38.5)
|
6 (54.5)
|
|
Missing
|
7 (17.9)
|
2 (18.2)
|
5 (12.8)
|
2 (18.2)
|
- irRC immune-related response criteria, RECIST Response Evaluation Criteria in Solid Tumors
